Molecular Diagnostics: A Global Strategic Business Report
San Jose, California (Vocus) October 14, 2010
Molecular diagnostics is a rapidly advancing market within the medical diagnostics market, backed by hectic activity in the biomarker research arena, and exploding new applications for these tests. Blood screening and infectious disease contribute to majority of the market. Nevertheless, genetic diseases, oncology, and pharmacogenomics are driving market growth. Molecular diagnostics market is being propelled by several growth factors. These factors include the requirement of automated and easy-to-handle techniques combining optimized sample preparation, analysis, and data evaluation in one. Another important factor is a requirement of swift diagnoses techniques that would diagnose disease condition and medical disorders quickly and offer a strong and consistent tool for quick therapy decisions. In terms of technological push, genomics and proteomics are the major drivers of the molecular diagnostic market. Nevertheless, nanobiotechnology and biochip would drive future growth in the molecular diagnostics market.
Recent advancements in molecular diagnostics include a shift towards near-patient testing practices, increasing number of innovative biomarkers, and an increased effort for clinically validating tests. In addition, the market is experiencing increasing competition, modifications in the regulatory environment, an improved role of personalized medicine, as well as consolidation within the area of molecular diagnostics.
The United States represents the largest market worldwide for molecular diagnostics, as stated by the new market research report on Molecular Diagnostics. Europe trails behind the US, with the two regions accounting for more than three-fourth share of the global molecular diagnostic market. However, Asia-Pacific is expected to spearhead growth over the forthcoming years, registering a CAGR of more than 15% during the analysis period. Segment wise, Infectious Disease Testing represents the largest market segment. Growth is forecast to emanate from Cancer Screening and Pharmacogenomics.
Major players profiled in the report include Abbott Molecular, Applera Corp., Biomérieux, ELITech Group, GE Healthcare, Gen-Probe Inc., Genzyme Corp., Novartis Vaccines & Diagnostics Inc., Siemens Healthcare Diagnostics, among others.
The report titled “Molecular Diagnostics: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the Molecular Diagnostics markets, current market trends, key growth drivers, recent product introductions, recent industry activity, and profiles of major/niche global as well as regional market participants. The study analyzes market data and analytics in value terms for the following geographic markets - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Key segments analyzed include Infectious Disease Testing, Pharmacogenomics, and Cancer Screening. In addition, a seven-year (2000-2006) historic analysis is provided for additional perspective.
For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Molecular_Diagnostics_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com/